Pivotal bioVenture Partners Fund I, L.P. - 05 Nov 2025 Form 3 Insider Report for Evommune, Inc.

Role
Director, 10%+ Owner
Signature
/s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I, L.P., By: Robert Hopfner, Managing Partner
Issuer symbol
EVMN on NYSE
Transactions as of
05 Nov 2025
Net transactions value
$0
Form type
3
Filing time
05 Nov 2025, 20:11:41 UTC
Previous filing
03 Aug 2023
Next filing
12 Nov 2025
SEC
View on sec.gov

Reporting Owners (3)

Name Relationship Address Signature Signature date CIK
Pivotal bioVenture Partners Fund I, L.P. Director, 10%+ Owner 501 SECOND STREET, SUITE 200, SAN FRANCISCO /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I, L.P., By: Robert Hopfner, Managing Partner 05 Nov 2025 0001695076
Pivotal bioVenture Partners Fund I G.P., L.P. Director, 10%+ Owner 501 SECOND STREET, SUITE 200, SAN FRANCISCO /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I G.P., L.P., By: Robert Hopfner, Managing Partner 05 Nov 2025 0001752862
Pivotal bioVenture Partners Fund I U.G.P. Ltd Director, 10%+ Owner 501 SECOND STREET, SUITE 200, SAN FRANCISCO /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I U.G.P. Ltd., By: Robert Hopfner, Managing Partner 05 Nov 2025 0001752847

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EVMN Series Seed Preferred Stock 05 Nov 2025 Common Stock 838,886 See footnotes F1, F5, F10
holding EVMN Series Seed Preferred Stock 05 Nov 2025 Common Stock 419,441 See footnotes F1, F6, F8, F9
holding EVMN Series A Preferred Stock 05 Nov 2025 Common Stock 324,578 See footnotes F2, F5, F10
holding EVMN Series A Preferred Stock 05 Nov 2025 Common Stock 908,821 See footnotes F2, F6, F8, F9
holding EVMN Series B Preferred Stock 05 Nov 2025 Common Stock 240,756 See footnotes F3, F5, F10
holding EVMN Series B Preferred Stock 05 Nov 2025 Common Stock 267,367 See footnotes F3, F6, F8, F9
holding EVMN Series C Preferred Stock 05 Nov 2025 Common Stock 36,812 See footnotes F4, F5, F10
holding EVMN Series C Preferred Stock 05 Nov 2025 Common Stock 36,812 See footnotes F4, F6, F8, F9
holding EVMN Series C Preferred Stock 05 Nov 2025 Common Stock 294,502 See footnotes F4, F7, F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series Seed Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's initial public offering (the "IPO"), all shares of Series Seed Preferred Stock will be converted into shares of Common Stock.
F2 The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.9557 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.
F3 The Series B Preferred Stock is convertible into Common Stock on a 1-for-7.8721 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B Preferred Stock will be converted into shares of Common Stock of the Issuer.
F4 The Series C Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C Preferred Stock will be converted into shares of Common Stock of the Issuer.
F5 Held directly by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited ("NFGHL").
F6 Held directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I").
F7 Held directly by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II").
F8 The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP I") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd ("Pivotal GP II"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd ("Pivotal Partners"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited ("NFIHL"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer.
F9 The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein.
F10 The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein.